The discovery that pancreatic tumors hijack nerve development pathways could reshape treatment strategies for one of medicine's most lethal cancers. This finding challenges the traditional view of cancer as purely a cellular disease, revealing how tumors actively recruit their own nervous system support networks to fuel growth and spread.
Researchers identified netrin-1, a protein normally guiding nerve growth during development, as a key driver of pancreatic cancer progression. In laboratory models using KRAS-mutant pancreatic cells—the genetic signature found in 90% of human pancreatic cancers—netrin-1 levels increased dramatically during tumor formation. The protein works through its receptor NEO1 to simultaneously promote sympathetic nerve infiltration into tumors and activate cancer cell pathways that enhance growth, invasion, and stem cell properties. When scientists knocked out the netrin-1 gene in mouse models, both nerve invasion and tumor development decreased substantially, extending survival times.
This research illuminates a sophisticated tumor ecosystem where cancer cells and nerves form mutually beneficial partnerships. Netrin-1 appears to serve dual roles: attracting sympathetic nerves that provide growth signals while directly activating focal adhesion kinase pathways that promote epithelial-mesenchymal transition—a critical step in metastasis. The protein upregulates key transcription factors ZEB1 and SOX9, which drive both cancer stemness and invasive behavior.
While promising, these findings emerge from mouse models and require human validation. The therapeutic potential of targeting netrin-1 or NEO1 represents an entirely new approach to pancreatic cancer, potentially disrupting both the tumor's internal growth machinery and its external nerve supply lines. This dual mechanism could prove more effective than current treatments that focus solely on cancer cells themselves.